The most advanced small cap stock screener is live!
TradeThePinnacle 1.0 is officially live.
Web browser streaming, Windows and Linux downloadable app at https://t.co/OuP129EEqF
Daily Livestream at: https://t.co/9f4DTf6HS1
#smallcaps#smallstocks#stockscreener#stocks #markets #stockmarket
CATALYST · $NTRP
Today · Corporate — Proxy Statement Filed
NextTrip, Inc. (NTRP) filed a definitive proxy statement (DEF 14A) regarding its 2027 Annual Meeting of Stockholders, scheduled for October 9, 2026.
The record date for voting is August 10, 2026, at which time 15,086,101 shares of common stock were outstanding.
The agenda includes the election of three Class III directors and the ratification of Haynie & Company as the independent auditor.
A significant portion of the filing concerns shareholder approval for share issuances exceeding 19.99% of outstanding
stock, as required by Nasdaq Listing Rule 5635(d).
These proposals relate to the conversion of a Senior Secured Convertible Promissory Note held by Lind Global Fund III
LP, as well as the conversion of Series A Convertible Preferred Stock and exercise of related warrants issued to various
investors and an insider between December 2025 and April 2026.
Use TradeThePinnacle to access this data.
CATALYST · $HOWL
Today · Corporate — Merger & PIPE Financing
On August 21, 2026, Werewolf Therapeutics,
Inc. entered into a definitive merger agreement to acquire Ambros Therapeutics, Inc. through a subsidiary merger.
The transaction is structured as a tax-free reorganization, with Ambros becoming a wholly owned subsidiary of Werewolf.
Upon closing, pre-merger Werewolf equityholders are expected to own approximately 6.8% of the combined company,
while Ambros stockholders and PIPE investors are expected to own 71.7% and 21.5%, respectively.
Concurrently, Werewolf entered into a securities purchase agreement for a $150.0 million private placement of common stock and
pre-funded warrants. These warrants, along with merger-related pre-funded warrants, carry an exercise price of $0.001 per share.
Additionally, Werewolf will issue non-transferable contingent value rights (CVRs) to existing stockholders,
Use TradeThePinnacle to access this data.
CATALYST · $BOC
Today · Corporate — Annual Meeting
On August 21, 2026, Boston Omaha Corporation (NYSE: BOC) filed a Form 8-K to provide a Regulation FD disclosure regarding its corporate
activities. The primary purpose of the filing is to announce and distribute a slide presentation prepared for the company’s Annual
Meeting, which took place on the same date.
This presentation has been made available to the public via the company’s website and is included as Exhibit 99.1 to the filing.
The document serves as a formal record of the materials presented to shareholders,
covering the company's strategic updates and operational performance.
In accordance with Regulation FD, the company specified that the information contained within Item 7.01 and the attached exhibit is furnished rather than
Use TradeThePinnacle to access this data.
CATALYST · $HOWL
Today · Corporate — Event
On August 21, 2026, Werewolf Therapeutics,
Inc. entered into a definitive merger agreement to acquire Ambros Therapeutics, Inc. through a subsidiary merger.
The transaction is structured as a tax-free reorganization, with Ambros becoming a wholly owned subsidiary of Werewolf.
Upon closing, pre-merger Werewolf equityholders are expected to own approximately 6.8% of the combined company,
while Ambros stockholders and PIPE investors are expected to own 71.7% and 21.5%, respectively.
Concurrently, Werewolf entered into a securities purchase agreement for a $150.0 million private placement of common stock and
pre-funded warrants. These warrants, along with merger-related pre-funded warrants, carry an exercise price of $0.001 per share.
Additionally, Werewolf will issue non-transferable contingent value rights (CVRs) to existing stockholders,
Use TradeThePinnacle to access this data.